Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1985 November; 78(11): 893–898.
PMCID: PMC1289995

Low-dose radioiodine given six-monthly in Graves' disease.


Experience using low-dose radioiodine given six-monthly instead of yearly in hyperthyroid patients with Graves' disease is reported. One hundred and thirty-five patients have been treated over a three-year period with 74 MBq (2 mCi) doses of 131I. Thirty-eight percent were controlled with a single dose. Those patients requiring more than one dose were treated with a further 74 MBq (2 mCi) 131I at six-monthly intervals until euthyroid. Using this approach, 46% were euthyroid one year after starting treatment, and 75% were euthyroid at two years. The incidence of hypothyroidism following treatment was 2.2% at one year, with a yearly incidence thereafter of 4-6%. Six-monthly scheduling of low-dose radioiodine in Graves' disease can reduce the time taken to become euthyroid, compared with conventional yearly low-dose treatments. Further follow up is required to confirm the present low incidence of hypothyroidism following treatment.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (694K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aro A, Huttunen JK, Lamberg BA, Pelkonen R, Ikkala E, Kuusisto A, Rissanen V, Salmi J, Tervonen S. Comparison of propranolol and carbimazole as adjuncts to iodine-131 therapy of hyperthyroidism. Acta Endocrinol (Copenh) 1981 Mar;96(3):321–327. [PubMed]
  • Becker DV. Choice of therapy for Graves' hyperthyroidism. N Engl J Med. 1984 Aug 16;311(7):464–466. [PubMed]
  • Connell JM, Hilditch TE, McCruden DC, Robertson J, Alexander WD. Effect of pretreatment with carbimazole on early outcome following radio-iodine (131I) therapy. Eur J Nucl Med. 1984;9(10):464–466. [PubMed]
  • Goolden AW, Fraser TR. Treatment of thyrotoxicosis with low doses of radioactive iodine. Br Med J. 1969 Aug 23;3(5668):442–443. [PMC free article] [PubMed]
  • Halnan KE. Risks from radioiodine treatment of thyrotoxicosis. Br Med J (Clin Res Ed) 1983 Dec 17;287(6408):1821–1822. [PMC free article] [PubMed]
  • Hamburger JI, Paul S. When and how to use higher 131-I doses for hyperthyroidism. N Engl J Med. 1968 Dec 19;279(25):1361–1365. [PubMed]
  • Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J (Clin Res Ed) 1984 Aug 11;289(6441):361–363. [PMC free article] [PubMed]
  • Lowdell CP, Dobbs HJ, Spathis GS, McCready VR, Cosgrove DO, Harmer CL. Low-dose 131I in treatment of Graves' disease. J R Soc Med. 1985 Mar;78(3):197–202. [PMC free article] [PubMed]
  • Scott GR, Forfar JC, Toft AD. Graves' disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131. Br Med J (Clin Res Ed) 1984 Aug 18;289(6442):399–400. [PMC free article] [PubMed]
  • Smith RN, Wilson GM. Clinical trial of different doses of 131-I in treatment of thyrotoxicosis. Br Med J. 1967 Jan 21;1(5533):129–132. [PMC free article] [PubMed]
  • Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med. 1984 Aug 16;311(7):426–432. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press